Ranjbarian Parivash, Goudarzi Farjam, Akya Alisha, Heidarinia Hana, Farasat Alireza, Rostamian Mosayeb
Department of Microbiology, Faculty of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Biologia (Bratisl). 2023 Mar 14:1-11. doi: 10.1007/s11756-023-01371-0.
No approved vaccine exists for yet. Outer membrane protein-K17 (OMPK17) is involved in pathogenesis. No information has been found about OMPK17 dominant epitopes in the literature. Therefore, this study aimed to predict both T cell and B cell epitopes of OMPK17 via immunoinformatics approaches. Both T cell (class-I and II) and B cell (linear and discontinuous) epitopes of OMPK17 were predicted. Several screening analyses were performed including clustering, immunogenicity, human similarity, toxicity, allergenicity, conservancy, docking, and structural/physicochemical suitability. The results showed that some regions of OMPK17 have more potential as epitopes. The most possible epitopes were found via several analyses including the selection of higher-scoring epitopes, the epitopes predicted with more tools, more immunogenic epitopes, the epitopes capable of producing interferon-gamma, the epitopes with more dissimilarity to human peptides, and non-toxic and non-allergenic epitopes. By comparing the best T cell and B cell epitopes, we reached a 25-mer peptide containing both T cell (class-I and class-II) and B cell (linear) epitopes and comprising appropriate physicochemical characteristics that are required for vaccine development. The in vitro/in vivo study of this peptide is recommended to clarify its actual efficiency and efficacy.
The online version contains supplementary material available at 10.1007/s11756-023-01371-0.
目前尚无针对[病原体名称未明确]的获批疫苗。外膜蛋白-K17（OMPK17）参与[病原体名称未明确]的发病机制。在文献中未找到有关OMPK17显性表位的信息。因此，本研究旨在通过免疫信息学方法预测OMPK17的T细胞和B细胞表位。对OMPK17的T细胞（I类和II类）和B细胞（线性和不连续）表位进行了预测。进行了多项筛选分析，包括聚类、免疫原性、与人的相似性、毒性、致敏性、保守性、对接以及结构/物理化学适宜性分析。结果表明，OMPK17的某些区域作为表位具有更大潜力。通过包括选择得分较高的表位、用更多工具预测的表位、免疫原性更强的表位、能够产生γ干扰素的表位、与人肽差异更大的表位以及无毒和无致敏性的表位等多项分析，找到了最可能的表位。通过比较最佳的T细胞和B细胞表位，我们得到了一个包含T细胞（I类和II类）和B细胞（线性）表位且具有疫苗开发所需适当物理化学特征的25聚体肽。建议对该肽进行体外/体内研究以阐明其实际效率和功效。
在线版本包含可在10.1007/s11756-023-01371-０查阅的补充材料。
